StockData

ProQR Therapeutics vs uniQure

PRQR and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PRQR and QURE compare

uniQure grew revenue faster over the last twelve months (30.2% versus 11.4% for ProQR Therapeutics).

ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −1351% at uniQure.

ProQR Therapeutics scores higher on the StockData Score (7 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPRQRQURE
Size and price
Market cap–$1.4B
Share price$1.15$20.78
Change, 1 year−47.0%−30.5%
Change, 5 years−84.0%−27.9%
Beta (5Y)2.583.14
Employees59221
StockData Score
Total score7 (better)4
Valuation score00
Growth score22
Performance score2 (better)0
Health score3 (better)2
Dividend score00
Valuation
P/S–77.2×
P/B–4.4×
FCF yield–−11.2%
Fair value–$6.42
Margin of safety–−224%
Growth
Revenue growth (TTM)11.4%30.2% (better)
Revenue growth, 5Y average–−15.6%
Profitability
Gross margin–92.5%
Operating margin−233% (better)−1072%
Net margin−229% (better)−1351%
FCF margin−273% (better)−865%
Return on equity−57.4% (better)−158%
Financial health
Debt / equity0.06 (better)0.15
Interest coverage–−3.4×
Current ratio3.4910.01 (better)
Altman Z-score–−0.51
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions57.6%96.0%
Held by insiders37.8%2.1%
Insider net buying, 12 months$1.3M (better)−$20.2M
Short interest, % of float–12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.